Scarica l'app Stockscreener
13.66
0.96%
0.13
Pre-mercato:
13.78
0.12
+0.88%
Precedente Chiudi:
$13.53
Aprire:
$13.38
Volume 24 ore:
2.12M
Relative Volume:
1.53
Capitalizzazione di mercato:
$1.51B
Reddito:
$-665.00K
Utile/perdita netta:
$-144.74M
Rapporto P/E:
-8.7976
EPS:
-1.5527
Flusso di cassa netto:
$-123.48M
1 W Prestazione:
-4.41%
1M Prestazione:
-7.14%
6M Prestazione:
-1.59%
1 anno Prestazione:
+261.38%
Intervallo 1D:
$13.20
$13.70
Intervallo di 1 settimana:
$13.20
$14.44
Portata 52W:
$3.11
$17.49
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Nome
Amylyx Pharmaceuticals Inc
Settore
Telefono
617-682-0917
Indirizzo
55 CAMBRIDGE PARKWAY, CAMBRIDGE
Compare AMLX vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
13.66 | 1.51B | -665.00K | -144.74M | -123.48M | -1.5527 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-03 | Iniziato | Stifel | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2025-06-24 | Iniziato | Guggenheim | Buy |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2025-05-30 | Iniziato | TD Cowen | Buy |
| 2025-04-07 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-11-18 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-03-18 | Downgrade | Mizuho | Buy → Neutral |
| 2024-03-11 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-07-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-03-31 | Iniziato | Mizuho | Buy |
| 2023-01-05 | Iniziato | BofA Securities | Buy |
| 2022-05-25 | Iniziato | Citigroup | Buy |
| 2022-04-01 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Amylyx Pharmaceuticals Inc Borsa (AMLX) Ultime notizie
Amylyx Pharmaceuticals Advances Novel Therapies for Rare Diseases: Avexitide, AMX0035, and AMX0114 Show Promise in Clinical Trials for PBH, Wolfram Syndrome, and ALS - Minichart
Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia - BioSpace
Amylyx Highlights Pipeline Progress in Updated Corporate Presentation - TipRanks
Amylyx Pharmaceuticals completes enrollment in Phase 3 LUCIDITY trial for PBH - Traders Union
Amylyx updates presentation: LUCIDITY and LUMINA enrollment complete; LUCIDITY topline due Q3 2026 - TradingView
Amylyx (NASDAQ: AMLX) details avexitide Phase 3 timing and cash runway into 2028 - Stock Titan
Amylyx Pharmaceuticals Q4 2025 earnings preview - MSN
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart
Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Amylyx Pharmaceuticals Inc (AMLX) Shares Gap Down to $13.78 on M - GuruFocus
Maven Securities LTD Makes New $951,000 Investment in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Fund Flows: Is Amylyx Pharmaceuticals Inc stock a smart retirement pickPortfolio Gains Report & Weekly Sector Rotation Insights - baoquankhu1.vn
Amylyx shares slip despite Q4 beat as investors focus on trial timeline - MSN
Amylyx Pharmaceuticals expands team to address urgent healthcare challenges - Traders Union
How Investors May Respond To Amylyx Pharmaceuticals (AMLX) Narrowed 2025 Losses And Expanded Shelf Capacity - simplywall.st
Buy Rating on Amylyx Pharmaceuticals Driven by Avexitide’s Commercial Potential and De-Risked Phase III PBH Program - TipRanks
First Light Asset Management LLC Purchases Shares of 3,355,882 Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Amylyx Pharmaceuticals, Inc. $AMLX Shares Sold by Boxer Capital Management LLC - MarketBeat
Commodore Capital Boosts Stake in Amylyx Pharmaceuticals - National Today
Commodore Capital LP Purchases Shares of 4,075,478 Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Braidwell LP Acquires Shares of 612,841 Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
437,391 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Purchased by Ally Bridge Group NY LLC - MarketBeat
Amylyx Pharmaceuticals Inc (AMLX) Shares Down 3.06% on Mar 13 - GuruFocus
Amylyx anticipates LUCIDITY trial results in Q3 2026 while advancing PBH market strategy - MSN
Amylyx Pharmaceuticals (NASDAQ:AMLX) Shares Gap DownHere's What Happened - MarketBeat
Amylyx Pharmaceuticals Highlights Avexitide LUCIDITY Phase 3 Enrollment, Q3 Data Timing at Leerink Conf. - Yahoo Finance
Amylyx Pharmaceuticals Maps High-Stakes Path to 2027 - TipRanks
[Form 4] Amylyx Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Amylyx (NASDAQ: AMLX) CFO receives new stock options and RSU grant - Stock Titan
Wall Street Zen Upgrades Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating - National Today
Amylyx Pharmaceuticals (AMLX) Price Target Increased by 17.82% to 15.17 - MSN
Winners Losers: How Amylyx Pharmaceuticals Inc. stock performs in weak economy2025 Market Sentiment & Real-Time Volume Surge Alerts - Naître et grandir
Amylyx Pharmaceuticals, Inc. $AMLX Position Increased by Vanguard Group Inc. - MarketBeat
Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Q1 EPS Forecast for Amylyx Pharmaceuticals Lifted by Analyst - MarketBeat
Amylyx (AMLX) Q4 2025 Earnings Call Transcript - AOL.com
H.C. Wainwright raises Amylyx stock price target to $34 on trial confidence - Investing.com India
H.C. Wainwright raises Amylyx stock price target to $34 on trial confidence By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals Inc (AMLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Amylyx Leadership Triggers Buzz With Major Insider Stock Moves - TipRanks
Amylyx (AMLX) -7.8%: Earnings Show $0 Revenue, Shelf Filing Adds Dilution Fear - Trefis
Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point (NASDAQ:AMLX) - Seeking Alpha
Tax-withholding sale by Amylyx Pharmaceuticals (AMLX) Chief Legal Officer - Stock Titan
Amylyx (AMLX) Co-CEO sells shares to cover RSU tax withholding - Stock Titan
Amylyx Pharmaceuticals (AMLX) CEO share sale covers tax obligations - Stock Titan
Amylyx (AMLX) CFO reports automatic tax-related sale of 7,909 shares - Stock Titan
Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Raised to $34.00 - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q4 2025 Earnings Call Transcript - Insider Monkey
The Bull Case For Amylyx Pharmaceuticals (AMLX) Could Change Following Narrower Losses And New Shelf Filings - simplywall.st
A Look At Amylyx Pharmaceuticals (AMLX) Valuation After Reduced Losses And Late Stage Pipeline Progress - Yahoo Finance
Amylyx Pharmaceuticals Inc Azioni (AMLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.75%
1.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):